Stock RXRX RECURSION PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Market Closed - Nasdaq
Other stock markets
 04:00:05 2024-04-23 pm EDT 		5-day change 1st Jan Change
7.695 USD +1.25% Intraday chart for Recursion Pharmaceuticals, Inc. +1.65% -21.96%
Apr. 18 Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing MT
Apr. 16 Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer MT

Evolution of the average Target Price on Recursion Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

142fb5f69171d54daf06cd.VdUhPW1aBOJ-fZgwfDIQsrGdImqP9w5XbUQn5_We0Z4.Y58SbjQ_PJAdS_Z8OXUi6OD-dR29vUglHA5Jgr3apNMAtGMPDgNQkAk87w~1dcd84e9bddff548e7ac20f47d6e4795

Analyst Recommendations on Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating MT
TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating MT
JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating MT
Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating MT
KeyBanc Adjusts Price Target on Recursion Pharmaceuticals to $15 From $12, Maintains Overweight Rating MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $35 From $33, Maintains Buy Rating MT
Morgan Stanley Lifts Price Target on Recursion Pharmaceuticals to $11 From $8 Amid NVIDIA Partnership, Keeps Equalweight Rating MT
Keybanc Adjusts Price Target on Recursion Pharmaceuticals to $12 From $20, Keeps Overweight Rating MT
Needham Starts Recursion Pharmaceuticals at Buy With $17 Price Target MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $33 From $42, Maintains Buy Rating MT
SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating MT
Berenberg Discover AI Seminar FA
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $42 From $38, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Recursion Pharmaceuticals to $9 From $8, Maintains Neutral Rating MT
KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target MT
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum PR
Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating MT
Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintains Buy Rating MT
Goldman Sachs Lowers Recursion Pharmaceuticals' Price Target to $7 From $9, Neutral Rating Kept MT
Berenberg Discover AI Seminar FA
BofA Securities Downgrades Recursion Pharmaceuticals to Neutral from Buy MT
Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $10 from $32, Keeps Neutral Rating MT
SVB Leerink Downgrades Recursion Pharmaceuticals to Market Perform from Outperform, Adjusts Price Target to $10 from $32 MT
Berenberg Bank Trims Recursion Pharmaceuticals' Price Target to $36 From $37 on Delayed REC-3599 Timeline; Buy Rating Kept MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
7.6 USD
Average target price
13 USD
Spread / Average Target
+71.05%
High Price Target
17 USD
Spread / Highest target
+123.68%
Low Price Target
10 USD
Spread / Lowest Target
+31.58%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Recursion Pharmaceuticals, Inc.

Needham & Co.
TD Cowen
JPMorgan Chase
KeyBanc Capital Markets
Morgan Stanley
Berenberg Bank
SVB Securities LLC
Goldman Sachs
BofA Securities
SVB Leerink
J.P. Morgan Chase

Ratings for Recursion Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RXRX Stock
  4. Consensus Recursion Pharmaceuticals, Inc.